


## SARS-CoV-2 3CLpro-IN-20

<b>Cat. No.:</b>	HY-155187		
<b>CAS No.:</b>	878985-00-3		
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>12</sub> BrNO <sub>2</sub>		
<b>Molecular Weight:</b>	366.21		
<b>Target:</b>	SARS-CoV		
<b>Pathway:</b>	Anti-infection		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 4.76 mg/mL (13.00 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.7307 mL	13.6534 mL	27.3067 mL
5 mM	0.5461 mL	2.7307 mL	5.4613 mL
10 mM	0.2731 mL	1.3653 mL	2.7307 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

SARS-CoV-2 3CLpro-IN-20 (Compound 5g) is a covalent SARS-CoV-2 3CLpro inhibitor (IC<sub>50</sub>: 0.43 μM, K<sub>i</sub>: ?0.33?μM)<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

0.43 μM (SARS-CoV-2 3CLpro)<sup>[1]</sup>

### REFERENCES

[1]. Bao HL, et al. Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors. Chem Biol Drug Des. 2023 Aug 10.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA